title: Adoptive T-cell therapy for B-cell malignancies.
abstract: The success of allogeneic hematopoietic cell transplantation (HCT) for B-cell malignancies is evidence that these tumors can be eliminated by T lymphocytes. This has encouraged the development of specific adoptive T-cell therapy, both for augmenting the anti-tumor effect of HCT and for patients not undergoing HCT. T cells that are capable of recognizing antigens expressed on malignant B cells may be recruited from the endogenous repertoire or engineered to express tumor-targeting receptors. Critical insights into the qualities of T cells that enable their persistence and function in vivo have been derived, and obstacles to effective T-cell-mediated tumor eradication are being elucidated. These advances provide the tools to translate adoptive T-cell transfer into reliable clinical therapies.
authors.affiliation: Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. mhudecek@fhcrc.org
authors.forename: Michael
authors.initials: M
authors.lastname: Hudecek
authors.forename: Larry D
authors.initials: LD
authors.lastname: Anderson
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Nishida
authors.forename: Stanley R
authors.initials: SR
authors.lastname: Riddell
mesh_terms: D019264:Adoptive Transfer / Q000379:methods*; D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology / Q000473:pathology*; D019337:Hematologic Neoplasms / Q000276:immunology / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D013601:T-Lymphocytes / Q000276:immunology* / Q000637:transplantation*; D014184:Transplantation, Homologous